Prenetics Announces Third Quarter 2024 Financial Results
Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand...
COVID-19
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price
CHICAGO, IL / ACCESSWIRE / November 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular...
Online Therapy Services Market to Expand by USD 16.16 Billion (2024-2028), Driven by Smartphone Adoption and Demand for Online Services, AI Redefining Market Landscape – Technavio
NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global online therapy services...
Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway
Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
Moderna to Present at Upcoming Conferences in December 2024
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming...
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,...
Aptevo Highlights the Potential of the Company’s Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA...
Telerehabilitation Systems Market to Expand by USD 532.9 Million (2024-2028), Rising Chronic Disease Cases Driving Revenue, AI Impacting Market Trends – Technavio
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global telerehabilitation systems market...
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing...
Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update
Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a...
FendX Signs LOI to Acquire IP and Enter a Supply Agreement For Supply of Eco-Friendly Sponge Wipes for Use in Cleaning High-Touch Surfaces
A synergist opportunity to enhance FendX's current product and IP portfolio to keep surfaces clean. Eco-friendly sponge wipes will offer...
First Patient Dosed in Aptevo’s Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of...
First Patient Dosed in Aptevo’s Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of...
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company...
electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is...
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov....
Update on Clinical Milestone – CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”...
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for...
SAS forecasts AI reality over hype for health care and life sciences in 2025
Pharma and health care industries take deliberate steps, not leaps, toward AI innovation and digital transformation CARY, N.C., Nov. 19,...